Thursday, December 5, 2024
6:00 PM ET – 6:30 PM ET – Dinner & Registration
6:30 PM ET – 8:00 PM ET – CME Meeting
Le Meridien/Sheraton Charlotte Hotel
555 S. McDowell Street
Charlotte, NC 28204
Meeting Room: Cardinal Ballroom
PROGRAM FEATURES
-
- Downloadable whiteboard animations
- Interactive, case-based learning environment
- Create-your-own personalized poster
PRESENTING FACULTY
Charles Vega, MD, FAAFP Health Sciences Clinical Professor UC Irvine Department of Family Medicine Director, UCI Program in Medical Education for the Latino Community Irvine, CA |
|
Kim Pfotenhauer DO, FACOFP, DABOM Assistant Dean of Clerkship Education Assistant Professor of Family Medicine Michigan State University College of Osteopathic Medicine East Lansing, MI |
PROGRAM OVERVIEW
The DETECT T1D Live Summit series has been designed to enable clinicians to help improve the screening and early detection of type 1 diabetes (T1D), as well as be on the forefront of therapeutic advances that delay T1D progression. Led by renowned experts, the series will utilize interactive case-based discussions and high-impact animations to better highlight these advances and provide practical tools and strategies for screening, follow-up, and treatment of early-stage T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Pediatric and Adult Endocrinologists, Pediatricians, Primary Care Providers and Endocrine Nurses. Additionally, accessible programming and tools have been designed for patients, relatives, and members of the general population. As discussed within program descriptions, activities are designed in a manner that allows learners to choose programming most relevant to their professional needs.
LEARNING OBJECTIVES
Upon completion of this activity, HCPs will have improved ability to:
- Describe the clinical presentation of T1D in adults compared to children
- Identify appropriate autoantibody screening strategies for T1D, including type, frequency, and number
- Interpret results from screening protocols to drive management decisions
- Discuss the latest clinical evidence for efficacy and tolerability of newly approved and investigational immunomodulatory agents
- Implement strategies for appropriate clinical monitoring and early screening in individuals at highest risk
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.5 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 CPEU.
PHARMACISTS AND PHARMACY TECHNICIANS (ACPE) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.5 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]